What is Checkpoint Therapeutics, Inc. (CKPT) stock price today?

Checkpoint Therapeutics, Inc. (CKPT) is currently trading at $4.26, up 0% today.

What is CKPT P/E ratio?

Checkpoint Therapeutics, Inc.'s P/E ratio is -3.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CKPT return on equity (ROE)?

Checkpoint Therapeutics, Inc.'s return on equity (ROE) is 438.14%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Checkpoint Therapeutics, Inc.'s market cap?

Checkpoint Therapeutics, Inc. has a market capitalization of $367.72M.

NASDAQ · Biotechnology

Checkpoint Therapeutics, Inc. (CKPT) Stock

$4.26 +0.00% NASDAQ: CKPT Healthcare

Checkpoint Therapeutics, Inc. is a clinical-stage company specializing in immunotherapy and targeted oncology.

Valuation

Metric	Value
Price	$4.26
Market Cap	$367.72M
P/E Ratio	-3.00
P/B Ratio	-13.39
P/S Ratio	8968.86
EPS (TTM)	$-1.42
52-Week High	$4.50
52-Week Low	$1.80
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	438.14%
ROA	-752.78%
ROCE	444.94%
Gross Margin	100.00%
Operating Margin	—
Net Margin	—
Debt/Equity	0.00
Current Ratio	0.37

Annual Financials (USD)

Metric	2020	2021	2022	2023	2024
Revenue	$1.0M	$0	$0	$0	$0
Operating Profit	$-23.0M	$-57.0M	$-58.0M	$-52.0M	$-56.0M
Net Profit	$-23.0M	$-57.0M	$-63.0M	$-52.0M	$-56.0M
EPS	$-4.13	$-7.45	$-7.09	$-2.77	$-1.42
Op Margin	-2170.3%	-21165.3%	-30381.8%	-50629.1%	-137009.8%

Balance Sheet (USD)

Metric	2020	2021	2022	2023	2024
Total Assets	$43.0M	$56.0M	$13.0M	$5.0M	$7.0M
Total Liabilities	$7.0M	$26.0M	$33.0M	$18.0M	$20.0M
Cash	$41.0M	$55.0M	$12.0M	$5.0M	$7.0M
Borrowings	$0	$0	$0	$0	$0

Cash Flow (USD)

Metric	2020	2021	2022	2023	2024
Operating Cash Flow	$-17.0M	$-26.0M	$-58.0M	$-48.0M	$-31.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$-2.0M	$-1.0M	$-3.0M	$7.0M	$7.0M
Net Cash Flow	$15.0M	$14.0M	$-43.0M	$-7.0M	$2.0M
Free Cash Flow	$-17.0M	$-26.0M	$-58.0M	$-48.0M	$-31.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-6.43
FCF Yield	-8.46%
Quick Ratio	0.37
Interest Coverage	0.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CLYMClimb Bio, Inc.	$10.29	-0.19%	-13.18	$591.02M	0.00%
GTHXG1 Therapeutics, Inc.	$7.16	+0.14%	-7.70	$377.75M	0.00%
INZYInozyme Pharma, Inc.	$4.00	+0.25%	-2.47	$258.25M	0.00%
ITOSiTeos Therapeutics, Inc.	$10.15	+0.20%	-3.89	$448.68M	0.00%
ORTXOrchard Therapeutics plc	$16.70	+0.30%	-27.38	$380.11M	0.00%

About Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. is a clinical-stage company specializing in immunotherapy and targeted oncology. Its mission involves discovering, advancing, and bringing to market innovative therapeutic solutions for individuals battling solid tumor cancers. The company's pipeline features several key candidates, including Cosibelimab, a leading fully-human IgG1 monoclonal antibody. This therapy is designed to directly bind to programmed death ligand-1 (PD-L1), thereby inhibiting its interaction with programmed death receptor-1 and B7.1 receptors. Another significant antibody in development is CK-302, a human agonistic antibody intended to bind and activate signaling within GITR-expressing cells. Beyond antibodies, Checkpoint Therapeutics is advancing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR mutation-positive non-small cell lung cancer. Its portfolio also includes CK-103, a highly selective and potent small molecule designed to inhibit bromodomain and extra-terminal (BET) bromodomains. Furthermore, a fully human, preclinical anti-carbonic anhydrase IX (CAIX) antibody is being developed, which aims to identify and destroy CAIX-expressing cells through both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). To broaden its reach, Checkpoint Therapeutics has established collaboration agreements with TG Therapeutics, Inc. These partnerships focus on the joint development and commercialization of specific assets related to its licenses in the area of hematological malignancies. Established in 2014, Checkpoint Therapeutics is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Fortress Biotech, Inc.

Checkpoint Therapeutics, Inc. is headquartered in US.

Checkpoint Therapeutics, Inc. (CKPT) stock trades at $4.26 with a market capitalization of $367.72M. The stock is valued at a price-to-earnings (P/E) ratio of -3.00, price-to-book of -13.39, price-to-sales of 8968.86. Over the past 52 weeks the stock has ranged between $1.80 and $4.50, and currently trades 5.3% below its 52-week high.

On profitability, Checkpoint Therapeutics, Inc. generates a return on equity (ROE) of 438.14% — well above the market average, a sign of a high-quality business, return on capital employed of 444.94%.

Official website: www.checkpointtx.com